Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
150 shown of 9,890 total abstracts
  1. Abstract 13022026-04-04 · 20:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-284 study)
    F. Andre, E. Winer · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  2. Abstract 18652026-04-01 · 15:45 CT · S406
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    M. Krop, S. Peters · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  3. Abstract 18672026-04-01 · 13:15 CT · Arie Crown Theater
    PALOMA-893: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    P. Schmid, L. Paz-Ares, M.C. Garassino · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  4. Abstract 15912026-04-05 · 20:30 CT · S406
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    H. Rugo, L. Paz-Ares · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  5. Abstract 18182026-04-04 · 19:15 CT · Arie Crown Theater
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    A. Spira, L. Paz-Ares · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  6. Abstract 12802026-04-03 · 18:45 CT · S100A
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    S. Modi, H. Borghaei, G. Curigliano, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  7. Abstract 15472026-04-04 · 16:00 CT · S406
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    N. Rizvi, J. Brahmer, M.C. Garassino, et al. · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  8. Abstract 18612026-04-05 · 21:00 CT · Hall B1
    MONALEESA-515: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    S. Modi, M.C. Garassino, S. Peters, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  9. Abstract 15932026-04-05 · 13:45 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-527
    A. Spira, S. Peters, S. Tolaney, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  10. Abstract 16352026-04-04 · 14:00 CT · S406
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    C. Robert, F. Andre · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  11. Abstract 16952026-04-01 · 19:00 CT · Arie Crown Theater
    Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-319
    E. Winer, S. Antonia · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  12. Abstract 17302026-04-02 · 20:15 CT · S100A
    IMpower-353: Tecentriq (atezolizumab) adjuvant in TNBC
    C. Saura, T. Mok, L. Paz-Ares, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  13. Abstract 18402026-04-04 · 18:15 CT · S406
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-916 study)
    F. Andre, A. Spira, M. Krop, et al. · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  14. Abstract 13302026-04-05 · 21:00 CT · Arie Crown Theater
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    S. Modi, C. Saura, N. Rizvi · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  15. Abstract 13972026-04-03 · 16:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-174 study)
    J. Cortes, C. Robert · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  16. Abstract 16722026-04-05 · 18:00 CT · S100A
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-195
    S. Modi, J. Brahmer, P. Schmid, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  17. Abstract 14822026-04-03 · 18:00 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-554 study)
    H. Borghaei, S. Peters, E. Winer, et al. · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  18. Abstract 14212026-04-04 · 14:00 CT · S100A
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-859
    M.C. Garassino, C. Saura · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  19. Abstract 12072026-04-04 · 16:00 CT · Arie Crown Theater
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-581
    S. Antonia, A. Spira · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  20. Abstract 19192026-04-02 · 14:15 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-48
    S. Peters, S. Tolaney · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  21. Abstract 10582026-04-01 · 13:00 CT · S100A
    IMpower-613: Tecentriq (atezolizumab) adjuvant in TNBC
    H. Rugo, N. Rizvi, M. Reck, et al. · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  22. Abstract 10422026-04-03 · 16:30 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-94
    F. Andre, M. Krop · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  23. Abstract 10372026-04-03 · 13:30 CT · S406
    ASCENT-99: Trodelvy (sacituzumab govitecan) maintenance in TNBC
    T. Mok, J. Brahmer, S. Modi, et al. · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  24. Abstract 11862026-04-05 · 14:45 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-320
    H. Rugo, S. Modi · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  25. Abstract 15732026-04-05 · 21:00 CT · Hall B1
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    M. Reck, M. Krop, L. Paz-Ares · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  26. Abstract 19292026-04-05 · 19:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-585 study)
    S. Modi, P. Schmid, F. Andre, et al. · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  27. Abstract 14562026-04-02 · 19:15 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-445
    T. Mok, H. Borghaei · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  28. Abstract 17142026-04-05 · 19:15 CT · S100A
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-535
    G. Curigliano, C. Robert, T. Mok, et al. · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  29. Abstract 10092026-04-03 · 20:00 CT · S100A
    PALOMA-165: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    M. Reck, C. Robert · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  30. Abstract 10332026-04-04 · 19:00 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with TNBC
    H. Rugo, M.C. Garassino, M. Krop, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  31. Abstract 16272026-04-02 · 21:45 CT · Arie Crown Theater
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    C. Saura, S. Modi, C. Robert · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  32. Abstract 13492026-04-05 · 18:00 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-74 study)
    A. Spira, G. Curigliano, J. Brahmer, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  33. Abstract 19302026-04-03 · 19:00 CT · S100A
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    C. Saura, N. Rizvi, S. Peters · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  34. Abstract 12442026-04-01 · 21:45 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-192
    M. Reck, J. Brahmer · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  35. Abstract 16342026-04-02 · 13:45 CT · S100A
    DESTINY-Breast-443: Enhertu (trastuzumab deruxtecan) neoadjuvant in HR+ breast cancer
    N. Rizvi, F. Andre · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  36. Abstract 15332026-04-04 · 21:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-412 study)
    T. Mok, M.C. Garassino, S. Antonia, et al. · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  37. Abstract 17692026-04-03 · 21:00 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-686 study)
    J. Brahmer, T. Mok · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  38. Abstract 19652026-04-03 · 18:30 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-907 study)
    A. Spira, J. Cortes, M. Krop, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  39. Abstract 11042026-04-05 · 18:15 CT · Arie Crown Theater
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-523
    J. Brahmer, N. Rizvi · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  40. Abstract 14602026-04-02 · 18:00 CT · E450
    ASCENT-466: Trodelvy (sacituzumab govitecan) 3L+ in TNBC
    F. Andre, T. Mok, L. Paz-Ares, et al. · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  41. Abstract 11422026-04-03 · 18:15 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-210
    H. Borghaei, S. Antonia, E. Winer, et al. · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  42. Abstract 16452026-04-02 · 14:15 CT · Arie Crown Theater
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    N. Rizvi, M. Reck, G. Curigliano, et al. · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  43. Abstract 12212026-04-02 · 19:15 CT · E450
    MONALEESA-135: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    A. Spira, J. Brahmer, H. Borghaei · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  44. Abstract 18802026-04-04 · 14:15 CT · S100A
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-396 study)
    J. Brahmer, F. Andre, S. Peters · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  45. Abstract 13212026-04-04 · 16:30 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-66
    H. Borghaei, T. Mok, S. Modi, et al. · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  46. Abstract 10632026-04-01 · 18:15 CT · S406
    Quality of life outcomes with Tecentriq in patients with TNBC
    S. Modi, J. Brahmer, T. Mok · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  47. Abstract 19062026-04-05 · 21:45 CT · Arie Crown Theater
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-412
    S. Modi, R. Herbst, H. Borghaei, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  48. Abstract 14922026-04-03 · 16:30 CT · S406
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-577
    R. Herbst, S. Antonia, H. Rugo, et al. · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  49. Abstract 16502026-04-02 · 18:15 CT · E450
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-840
    E. Winer, A. Spira · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  50. Abstract 12752026-04-03 · 15:00 CT · Arie Crown Theater
    Long-term follow-up of Enhertu maintenance for HR+ breast cancer: DESTINY-Breast-513
    S. Antonia, S. Peters, J. Cortes, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  51. Abstract 16712026-04-03 · 16:30 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-624 study)
    S. Antonia, H. Borghaei, T. Mok, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  52. Abstract 11632026-04-04 · 16:15 CT · S100A
    MONARCH-177: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    P. Schmid, E. Winer · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  53. Abstract 12652026-04-03 · 13:15 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-691 study)
    T. Mok, E. Winer · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  54. Abstract 17782026-04-01 · 16:00 CT · E450
    IMpower-364: Tecentriq (atezolizumab) adjuvant in TNBC
    S. Tolaney, S. Peters, S. Modi · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  55. Abstract 16392026-04-01 · 13:45 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-515 study)
    L. Paz-Ares, S. Antonia, M. Krop, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  56. Abstract 14182026-04-02 · 15:45 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-907
    J. Cortes, C. Robert, A. Spira, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  57. Abstract 13902026-04-02 · 19:15 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-674
    H. Rugo, G. Curigliano, S. Modi, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  58. Abstract 17012026-04-02 · 14:15 CT · Hall B1
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-977
    C. Saura, M.C. Garassino, F. Andre · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  59. Abstract 13352026-04-03 · 14:15 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-975
    G. Curigliano, A. Spira, J. Cortes, et al. · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  60. Abstract 14252026-04-02 · 13:15 CT · Arie Crown Theater
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-26
    M. Krop, J. Brahmer, G. Curigliano · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  61. Abstract 10152026-04-02 · 18:45 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-366 study)
    P. Schmid, F. Andre, H. Borghaei, et al. · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  62. Abstract 14882026-04-05 · 13:00 CT · Arie Crown Theater
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-205
    E. Winer, M. Reck, P. Schmid, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  63. Abstract 19992026-04-01 · 16:30 CT · S100A
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    M. Reck, J. Cortes, J. Brahmer · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  64. Abstract 14872026-04-05 · 20:00 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-410
    H. Borghaei, H. Rugo, C. Robert · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  65. Abstract 19002026-04-02 · 20:15 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-205
    J. Cortes, H. Borghaei · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  66. Abstract 13982026-04-01 · 19:00 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-946
    T. Mok, M. Reck, M.C. Garassino, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  67. Abstract 17742026-04-01 · 21:45 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-377
    R. Herbst, C. Saura · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  68. Abstract 14382026-04-02 · 21:00 CT · Hall B1
    Quality of life outcomes with Trodelvy in patients with TNBC
    H. Rugo, S. Modi · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  69. Abstract 11852026-04-02 · 13:00 CT · S100A
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-61
    S. Peters, A. Spira · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  70. Abstract 17842026-04-01 · 19:45 CT · S100A
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-595
    P. Schmid, F. Andre, L. Paz-Ares, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  71. Abstract 14582026-04-02 · 20:30 CT · S100A
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-550
    F. Andre, E. Winer · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  72. Abstract 16632026-04-05 · 20:45 CT · S100A
    ASCENT-38: Trodelvy (sacituzumab govitecan) 3L+ in TNBC
    S. Antonia, H. Rugo, S. Peters, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  73. Abstract 10662026-04-04 · 14:15 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-114
    H. Borghaei, J. Brahmer, H. Rugo, et al. · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  74. Abstract 16752026-04-04 · 20:45 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-53
    R. Herbst, M. Krop, J. Brahmer, et al. · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  75. Abstract 11442026-04-02 · 13:45 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-463
    C. Saura, H. Rugo, F. Andre · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  76. Abstract 12582026-04-02 · 15:30 CT · S406
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-86
    S. Antonia, M. Krop · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  77. Abstract 17782026-04-03 · 15:00 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-802
    S. Peters, H. Rugo, M.C. Garassino, et al. · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  78. Abstract 18492026-04-01 · 16:15 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-714
    F. Andre, M. Reck · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  79. Abstract 13232026-04-05 · 18:15 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-662 study)
    N. Rizvi, S. Antonia, T. Mok, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  80. Abstract 15792026-04-02 · 18:45 CT · E450
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-371
    E. Winer, S. Modi, F. Andre, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  81. Abstract 12612026-04-01 · 13:15 CT · S100A
    Long-term follow-up of Trodelvy neoadjuvant for TNBC: ASCENT-238
    F. Andre, M. Reck, S. Modi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  82. Abstract 14702026-04-02 · 21:15 CT · S406
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-504
    S. Tolaney, C. Saura, P. Schmid · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  83. Abstract 16682026-04-03 · 13:45 CT · E450
    IMpower-14: Tecentriq (atezolizumab) 3L+ in TNBC
    A. Spira, J. Brahmer, C. Saura, et al. · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  84. Abstract 13162026-04-01 · 20:15 CT · Hall B1
    OlympiA-610: Lynparza (olaparib) 2L in HR+ breast cancer
    S. Tolaney, L. Paz-Ares, G. Curigliano, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  85. Abstract 14772026-04-04 · 13:15 CT · S100A
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-217
    N. Rizvi, H. Borghaei, S. Tolaney, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  86. Abstract 17072026-04-05 · 15:15 CT · E450
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-78
    H. Borghaei, R. Herbst · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  87. Abstract 15812026-04-01 · 18:45 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-676
    C. Saura, S. Modi, L. Paz-Ares · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  88. Abstract 16422026-04-01 · 14:45 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-858 study)
    M.C. Garassino, L. Paz-Ares, G. Curigliano, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  89. Abstract 19422026-04-01 · 20:30 CT · S406
    MONALEESA-192: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    S. Peters, M. Reck, N. Rizvi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  90. Abstract 13372026-04-01 · 21:00 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-312
    S. Modi, A. Spira, L. Paz-Ares, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  91. Abstract 15212026-04-05 · 14:00 CT · Hall B1
    IMpower-728: Tecentriq (atezolizumab) neoadjuvant in TNBC
    N. Rizvi, S. Peters, C. Robert · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  92. Abstract 18382026-04-04 · 21:30 CT · E450
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-370
    P. Schmid, A. Spira, H. Borghaei, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  93. Abstract 11752026-04-04 · 15:15 CT · Arie Crown Theater
    PALOMA-224: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    N. Rizvi, M.C. Garassino · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  94. Abstract 18652026-04-02 · 16:45 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-470 study)
    H. Borghaei, J. Brahmer, J. Cortes, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  95. Abstract 17502026-04-01 · 16:15 CT · Hall B1
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-958
    L. Paz-Ares, M. Krop · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  96. Abstract 15862026-04-03 · 13:30 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-587
    S. Tolaney, N. Rizvi, H. Rugo, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  97. Abstract 15142026-04-04 · 19:00 CT · S100A
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-172
    S. Modi, C. Robert, J. Brahmer, et al. · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  98. Abstract 12692026-04-05 · 16:15 CT · Hall B1
    PALOMA-640: Ibrance (palbociclib) 1L in HR+ breast cancer
    M.C. Garassino, H. Rugo, G. Curigliano, et al. · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  99. Abstract 16862026-04-03 · 15:30 CT · E450
    Long-term follow-up of Enhertu 1L for HR+ breast cancer: DESTINY-Breast-538
    J. Cortes, P. Schmid, M. Reck · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  100. Abstract 14362026-04-01 · 16:45 CT · Arie Crown Theater
    ASCENT-667: Trodelvy (sacituzumab govitecan) 1L in TNBC
    T. Mok, H. Rugo, R. Herbst, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  101. Abstract 15442026-04-02 · 21:15 CT · S100A
    Long-term follow-up of Tecentriq maintenance for TNBC: IMpower-139
    M.C. Garassino, S. Tolaney, S. Antonia · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  102. Abstract 17352026-04-03 · 15:30 CT · S100A
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-504
    N. Rizvi, S. Antonia, H. Rugo, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  103. Abstract 17392026-04-03 · 21:00 CT · S406
    PALOMA-805: Ibrance (palbociclib) 3L+ in HR+ breast cancer
    S. Antonia, S. Tolaney, M.C. Garassino, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  104. Abstract 19242026-04-01 · 19:45 CT · Hall B1
    MONALEESA-127: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    E. Winer, H. Rugo · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  105. Abstract 11432026-04-05 · 21:45 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-198 study)
    E. Winer, S. Antonia, H. Rugo · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  106. Abstract 16282026-04-02 · 15:30 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-846 study)
    S. Tolaney, H. Borghaei, L. Paz-Ares, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  107. Abstract 11022026-04-05 · 15:15 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-340
    J. Brahmer, H. Rugo, A. Spira · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  108. Abstract 10042026-04-01 · 15:45 CT · Hall B1
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-248
    J. Cortes, M.C. Garassino, S. Modi · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  109. Abstract 10972026-04-02 · 19:15 CT · S406
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-24
    G. Curigliano, R. Herbst, A. Spira · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  110. Abstract 13272026-04-03 · 15:30 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-368 study)
    E. Winer, T. Mok · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  111. Abstract 12772026-04-04 · 15:30 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-238 study)
    N. Rizvi, H. Borghaei, M.C. Garassino, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  112. Abstract 11222026-04-04 · 21:15 CT · S100A
    MONARCH-204: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    N. Rizvi, S. Tolaney, L. Paz-Ares, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  113. Abstract 18882026-04-05 · 21:45 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-17 study)
    P. Schmid, C. Saura · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  114. Abstract 10492026-04-03 · 19:45 CT · S100A
    ASCENT-549: Trodelvy (sacituzumab govitecan) neoadjuvant in TNBC
    S. Peters, G. Curigliano, J. Brahmer, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  115. Abstract 16882026-04-02 · 20:45 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-687 study)
    J. Cortes, E. Winer, T. Mok · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  116. Abstract 10802026-04-02 · 13:00 CT · S406
    Long-term follow-up of Enhertu 2L for HR+ breast cancer: DESTINY-Breast-321
    E. Winer, S. Modi, F. Andre, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  117. Abstract 13812026-04-04 · 19:30 CT · Arie Crown Theater
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-936
    J. Cortes, P. Schmid · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  118. Abstract 14692026-04-03 · 19:45 CT · S100A
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    A. Spira, R. Herbst, E. Winer · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  119. Abstract 12942026-04-04 · 18:30 CT · Hall B1
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-68
    S. Antonia, S. Peters, J. Brahmer, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  120. Abstract 15462026-04-05 · 20:30 CT · Arie Crown Theater
    PALOMA-477: Ibrance (palbociclib) 1L in HR+ breast cancer
    H. Rugo, L. Paz-Ares, F. Andre, et al. · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  121. Abstract 10122026-04-05 · 18:15 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-435
    P. Schmid, E. Winer, H. Borghaei · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  122. Abstract 17652026-04-04 · 19:00 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-92 study)
    S. Tolaney, M.C. Garassino, C. Robert, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  123. Abstract 14682026-04-05 · 20:45 CT · S100A
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-284
    S. Modi, S. Peters, H. Rugo, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  124. Abstract 17242026-04-05 · 13:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-113 study)
    H. Borghaei, J. Brahmer, P. Schmid, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  125. Abstract 15082026-04-03 · 18:15 CT · E450
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-816
    N. Rizvi, S. Modi, L. Paz-Ares, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  126. Abstract 16272026-04-02 · 13:45 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-889 study)
    C. Robert, J. Cortes, T. Mok · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  127. Abstract 16672026-04-03 · 16:00 CT · E450
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-565
    S. Modi, H. Rugo, M. Reck · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  128. Abstract 16332026-04-02 · 15:30 CT · Arie Crown Theater
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-445
    M. Krop, C. Saura, L. Paz-Ares, et al. · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  129. Abstract 13752026-04-04 · 20:00 CT · S100A
    MONALEESA-688: Kisqali (ribociclib) 2L in HR+ breast cancer
    M. Reck, N. Rizvi, C. Robert · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  130. Abstract 12272026-04-02 · 14:15 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-870
    F. Andre, C. Saura · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  131. Abstract 19752026-04-03 · 18:30 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-242 study)
    N. Rizvi, M.C. Garassino · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  132. Abstract 15522026-04-04 · 21:15 CT · Hall B1
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-783
    J. Cortes, R. Herbst, S. Modi, et al. · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  133. Abstract 11582026-04-02 · 19:15 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-173
    N. Rizvi, S. Modi, S. Antonia, et al. · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  134. Abstract 19272026-04-03 · 20:30 CT · Hall B1
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-507
    S. Tolaney, S. Peters, J. Cortes · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  135. Abstract 16052026-04-01 · 20:30 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-950 study)
    C. Saura, J. Cortes · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  136. Abstract 17162026-04-04 · 18:15 CT · E450
    MONARCH-996: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    N. Rizvi, T. Mok, S. Peters, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  137. Abstract 14052026-04-05 · 18:15 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-678 study)
    N. Rizvi, J. Brahmer, F. Andre, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  138. Abstract 17012026-04-02 · 15:00 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-561
    C. Saura, C. Robert, T. Mok · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  139. Abstract 15542026-04-02 · 20:15 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-866 study)
    C. Robert, L. Paz-Ares, G. Curigliano, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  140. Abstract 13632026-04-05 · 19:45 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-72
    M. Reck, H. Rugo, M.C. Garassino · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  141. Abstract 11762026-04-05 · 20:15 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-88 study)
    F. Andre, M. Krop · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  142. Abstract 12482026-04-02 · 14:15 CT · Arie Crown Theater
    MONALEESA-637: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    A. Spira, C. Robert, P. Schmid, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  143. Abstract 16702026-04-03 · 18:00 CT · Hall B1
    PALOMA-859: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    M. Krop, H. Rugo, E. Winer, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  144. Abstract 18242026-04-05 · 19:00 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-247 study)
    J. Brahmer, L. Paz-Ares, G. Curigliano, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  145. Abstract 13532026-04-02 · 15:00 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-454
    S. Tolaney, S. Modi, S. Peters, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  146. Abstract 18352026-04-04 · 13:00 CT · S406
    PALOMA-504: Ibrance (palbociclib) 3L+ in HR+ breast cancer
    P. Schmid, C. Robert, H. Borghaei, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  147. Abstract 11792026-04-04 · 13:30 CT · S406
    MONARCH-796: Verzenio (abemaciclib) 1L in HR+ breast cancer
    J. Cortes, S. Modi, M. Krop, et al. · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  148. Abstract 16162026-04-02 · 15:30 CT · S406
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-502
    E. Winer, N. Rizvi, C. Robert · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  149. Abstract 14352026-04-03 · 20:45 CT · E450
    OlympiA-904: Lynparza (olaparib) neoadjuvant in HR+ breast cancer
    S. Tolaney, S. Peters, S. Antonia · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  150. Abstract 10302026-04-01 · 21:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-311 study)
    J. Brahmer, G. Curigliano, H. Borghaei · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.